Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Brukinsa
Pharma
Why Lilly is betting on 2nd-line CLL despite 1st-line wins
Lilly is defying the typical earlier-is-better strategy of cancer drug commercialization.
Angus Liu
Dec 9, 2025 7:30am
AbbVie, BeOne end BTK inhibitor patent fight
Oct 2, 2025 10:29am
Trial results show value of Lilly's Jaypirca in front-line CLL
Sep 8, 2025 11:37am
BeOne widens BTK lead over AstraZeneca
Aug 6, 2025 10:55am
BeiGene's Brukinsa surpasses AZ’s Calquence in quarterly sales
Feb 27, 2025 10:56am
Should BeiGene or Legend sell itself in 2025?
Jan 9, 2025 9:15am
